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OBJECTIVE — To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effec-
tively inhibits glucagon levels than the sulfonylurea glimepiride during a meal.
RESEARCH DESIGN AND METHODS — Glucagon responses to a standard meal were
measured at baseline and study end point (mean 1.8 years) in a trial evaluating add-on therapy
to metformin with 50 mg vildagliptin b.i.d. compared with glimepiride up to 6 mg q.d. in type
2 diabetes (baseline A1C 7.3  0.6%).
RESULTS — A1C and prandial glucose area under the curve (AUC)0–2 h were reduced
similarly in both groups, whereas prandial insulin AUC0–2 h increased to a greater extent
by glimepiride. Prandial glucagon AUC0–2h(baseline 66.6  2.3 pmol   h
1   l
1) decreased by
3.4 1.6 pmol  h
1  l
1 by vildagliptin (n137) and increased by 3.8 1.7 pmol  h
1  l
1 by
glimepiride (n  121). The between-group difference was 7.3  2.1 pmol   h
1   l
1 (P  0.001).
CONCLUSIONS — Vildagliptin therapy but not glimepiride improves postprandial -cell
function, which persists for at least 2 years.
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G
lucagon levels are increased in type
2 diabetes because of impaired glu-
cose-mediated suppression of glu-
cagon secretion resulting in increased
hepatic glucose output with subsequent
hyperglycemia(1).Improvedglycemiaby
the dipeptidyl peptidase-4 inhibitor,
vildagliptin (2), is mediated primarily by
improved - and -cell sensitivity to glu-
cose (3). As an add-on to metformin,
vildagliptin displays equal efﬁcacy as
glimepiride, with the added beneﬁts of a
much lower risk of hypoglycemia and no
weight gain (4). Here we report prandial
assessments of glucagon levels and insu-
lin secretion rates after up to 2 years of
therapy with the two drugs.
RESEARCH DESIGN AND
METHODS— The study was an ex-
tension to 2 years of a previously de-
scribed study (4). Standard meal
challenge was performed in selected cen-
ters at last treatment visit after adminis-
tration of a morning dose of metformin
plus 50 mg vildagliptin or up to 6 mg
glimepiride (mean treatment period 1.8
years). Doses were selected to achieve
comparable improvements in glycemia.
After an overnight fast, a mixed meal was
served (orange juice [180 ml], two slices
[60 g] of white bread, 30 g jam, 15 g but-
ter or margarine, 120 ml whole milk
[3–4% fat] or equivalent amount of
cheese plus 120 ml water, and, if desired,
decaffeinated coffee or tea; 510 kcal, with
50% from carbohydrate, 38% from fat,
and 12% from protein). Blood samples
were taken before the meal and at 15, 30,
60, 90, 120, 180, and 240 min.
Analytical determinations
Plasma glucose concentration was de-
termined by the glucose oxidase
method (Beckman Glucose Analyzer II;
Beckman Instruments, Fullerton, CA).
Plasma insulin, C-peptide, and gluca-
gon concentrations were determined by
radioimmunoassay (Diagnostics Prod-
ucts, Los Angeles, CA). Plasma intact
glucagon-like peptide (GLP)-1 concen-
trationwasmeasuredbyELISAusingan
NH2-terminal–speciﬁc antibody (Linco
Research, St. Charles, MO) by Novartis.
Calculations
Insulin secretory rate was determined as
described previously (5). The absolute
andincremental/decrementalareasunder
the curve (AUCs) for time 0–2 h after the
meal were calculated using the trapezoi-
dal method. End point changes from
baseline were assessed using ANCOVA.
Ethics
The study was conducted in accordance
with the Declaration of Helsinki. It was
reviewed by an independent ethics com-
mittee or institutional review board for
each center. Written informed consent
was obtained from each subject.
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were as follows: patient demographics of
the subpopulation who participated in
the meal challenge (n  259) were essen-
tially the same as reported previously (4).
Mean baseline A1C was 7.3  0.6%.
A1C, glucose, and insulin
At the follow-up meal test (up to 2 years
after start; mean 1.8 years), A1C was re-
ducedby0.10.9%inthevildagliptin
group (n  137) versus 0.2  0.8% in
theglimepiridegroup(n121).Prandial
glucose AUC0–2 h was similarly reduced
inbothgroups(1.7mmol h
1 l
1for
vildagliptin vs. 2.1 mmol   h
1   l
1 for
glimepiride), whereas prandial insulin 1
AUC0–2 hincreased to a greater extent in
the glimepiride group (33  18 pmol  
h
1 l
1for vildagliptin vs. 91 19 pmol  
h
1   l
1 for glimepiride) (P  0.017).
Glucagon, GLP-1, and insulin
secretion
Prandial glucagon AUC0–2 h decreased
from baseline with vildagliptin treatment
but increased with glimepiride (3.4 
1.6 pmol   h
1   l
1 for vildagliptin vs.
3.81.7pmol h
1 l
1forglimepiride;
P  0.001; Fig. 1A). Prandial intact
GLP-1AUC0–2hincreasedinbothgroups
but was much larger after vildagliptin
(18.8  1.8 pmol   h
1   l
1 for vildaglip-
tin vs. 1.6  1.7 pmol   h
1   l
1 for
glimepiride; Fig. 1B). Insulin secretion
rate relative to glucose (0–2 h) increased
in both groups (4.3  0.9 pmol/min/m
2/
mmol/l for glimepiride vs. 1.6  0.9
pmol/min/m
2/mmol/l for vildagliptin;
P  0.022; Fig. 1C). Prandial insulin-to-
glucagon ratio (AUC0–2 h for insulin/
AUC0–2 h for glucagon) changed by
1.1  9.3 (baseline 7.4  0.4) pmol
insulin/pmol glucagon in the vildagliptin
group versus 7.3  9.8 (baseline 7.1 
0.4) pmol insulin/pmol glucagon in the
glimepiride group (P  0.62).
Insulin resistance
Fasting insulin (15.2  1.6 pmol/l for
glimepiridevs.5.71.6pmol/lforvilda-
gliptin; P  0.001) and HOMA-IR
(0.11  0.10 for vildagliptin vs. 0.63 
0.10 for glimepiride; P  0.001; Fig. 1D)
increased in both treatment groups with
larger increases with glimepiride.
CONCLUSIONS — Vildagliptin re-
duces glucagon levels after a standard
mixed meal in patients with type 2 diabe-
tes who are treated with metformin, as
was previously demonstrated in individ-
uals with IGT (6), IFG (7), and type 1
diabetes (8). This effect appears to be the
result of a GLP-1–induced improvement
in glucose sensitivity of the -cells (3,9).
In contrast, glimepiride increases gluca-
gon levels, which may be the result of at-
tenuation of the glucose sensitivity of the
-cells with uncoupling of glucose de-
pendency (10).
With respect to -cell function,
vildagliptin increases glucose sensitiv-
ity (11), whereas indirect data suggest
that sulfonylurea uncouples the glucose
dependency of the -cells, which atten-
uates glucose sensitivity (10). In this
study, this resulted in increased insulin
secretion by both treatments, although
vildagliptin did not increase the insulin
secretion rate as much as glimepiride.
The greater insulin secretion rate in the
glimepiride group was balanced by less
insulin resistance in the vildagliptin
group, as reﬂected by HOMA-IR and
lower postprandial glucagon levels re-
sulting in similar glucose levels.
In summary, prandial glucagon is in-
creased by glimepiride but reduced by
vildagliptin. Hence, vildagliptin effec-
tively targets glucagon secretion in the
treatment of diabetes. This together with
the lesser increase in insulin by vildaglip-
tin than by glimepiride may provide a
pathophysiological explanation for the
observation that vildagliptin’s effect of re-
ducing A1C levels below 7% is associated
with much less hypoglycemia than
glimepiride while being associated with
the same A1C reduction (4).
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